NewcelX director reports option holdings in Form 3

NewcelX Ltd. director Alexander Zwyer filed an initial Form 3 reporting derivative holdings in the company.

Accepted by SEC EDGAR 03/18/2026 - 06:43 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

NewcelX Ltd. director Alexander Zwyer filed an initial Form 3 reporting derivative holdings in the company. He holds an option to purchase 50,143 ordinary shares at an exercise price of 7.6200, expiring on November 4, 2035.

A footnote explains that options to purchase 4,178 ordinary shares are currently vested and exercisable. The remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to his continued service.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Zwyer Alexander

Role Director

Type	Security	Shares	Price	Value
Holding	Option to Purchase Ordinary Shares	--	--	--

Holdings: Option to Purchase Ordinary Shares — 50,143 contracts (Direct)

Footnotes (1)

1. F1. As of the date of this Form 3, options to purchase 4,178 ordinary shares are vested and currently exercisable. The remaining options vest and become exercisable beginning on May 4, 2026 in 11 equal installments on a quarterly basis, subject to the Reporting Person's continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does NewcelX (NCEL) director Alexander Zwyer report on this Form 3?

He reports holding an option to purchase 50,143 NewcelX ordinary shares. The option has an exercise price of 7.6200 and expires on November 4, 2035, providing long-term potential equity exposure if the options are exercised over time.

How many NewcelX (NCEL) options held by Alexander Zwyer are currently vested?

As of this Form 3, options to purchase 4,178 ordinary shares are vested and currently exercisable. This represents the portion of his 50,143-share option grant that he can exercise immediately, with the rest subject to a future vesting schedule.

What is the vesting schedule for Alexander Zwyer’s remaining NewcelX (NCEL) options?

The remaining options vest and become exercisable in 11 equal quarterly installments starting on May 4, 2026. Vesting is conditioned on Alexander Zwyer’s continued service, meaning he must remain in his role to receive future installments.

What is the expiration date and exercise price of Alexander Zwyer’s NewcelX (NCEL) stock options?

The option to purchase 50,143 ordinary shares has an exercise price of 7.6200 and expires on November 4, 2035. After that date, any unexercised options lapse and can no longer be converted into ordinary shares.

Is this NewcelX (NCEL) Form 3 a report of a new insider transaction?

This Form 3 functions as an initial statement of beneficial ownership rather than a new trade. It discloses Alexander Zwyer’s existing option position in NewcelX, including vested and unvested portions, without indicating a recent purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Zwyer Alexander

(Last) (First) (Middle)

C/O NEWCELX LTD.

THE CIRCLE 6

(Street)

ZURICH 8058

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NewcelX Ltd. [ NCEL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Ordinary Shares	(1)	11/04/2035	Ordinary Shares	50,143	$7.62	D

Explanation of Responses:

1. As of the date of this Form 3, options to purchase 4,178 ordinary shares are vested and currently exercisable. The remaining options vest and become exercisable beginning on May 4, 2026 in 11 equal installments on a quarterly basis, subject to the Reporting Person's continued service.

	/s/ Alexander Zwyer	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)